Segmented Peptides for Cholesterol Efflux via ABCA1 Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for treating cardiovascular disease, particularly atherosclerosis, face challenges in effectively manipulating the reverse cholesterol transport pathway due to limitations with full-length Apo A-I proteins, such as production complexity and immunogenic responses, necessitating alternative compositions and methods for cholesterol efflux.
Innovation Solution
Development of a family of non-naturally occurring peptides with high-affinity binding to ABCA1, stimulating cholesterol efflux and stabilizing the ABCA1 transporter, which can be used alone or in combination with other pharmacological agents to treat cardiovascular disease, dyslipidemia, and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full-length Apo A-I proteins are used to mediate reverse cholesterol transport, then cholesterol efflux activity is achieved, but production complexity and immunogenic responses increase
Solution Approach 1:
The patent segments the full-length Apo A-I protein into functional peptide motifs (specifically residues 1-20 and 44-65) that retain cholesterol efflux activity. This segmentation reduces production complexity while maintaining therapeutic effectiveness, as the peptides can be synthesized more easily than full-length proteins.
Solution Approach 2:
The patent extracts the critical functional elements from full-length Apo A-I, identifying and isolating specific peptide sequences (including the 1-20 and 44-65 regions) that are sufficient for mediating reverse cholesterol transport. This extraction eliminates unnecessary portions of the protein, reducing immunogenicity and production complexity.
2Reliability
If full-length Apo A-I proteins are used to mediate reverse cholesterol transport, then cholesterol efflux activity is achieved, but immunogenic responses increase
Solution Approach 1:
By segmenting the full-length protein into smaller peptide motifs, the patent reduces the molecular size and foreignness that trigger immunogenic responses. The peptides maintain functional activity while presenting a reduced immunogenic profile compared to full-length Apo A-I.
Solution Approach 2:
The patent extracts and removes portions of the full-length protein that are most likely to elicit immunogenic responses, retaining only the essential functional motifs. This extraction strategy maintains therapeutic activity while minimizing immune system reactions.
3Device complexity
If non-naturally occurring peptides are developed to replace full-length Apo A-I, then production complexity is reduced, but binding affinity to ABCA1 must be maintained
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the peptide sequences (such as the 1-20 and 44-65 motifs) to enhance binding affinity to ABCA1. These localized structural and sequence features are specifically designed to maintain high-affinity interaction with the transporter, compensating for the reduced size compared to full-length protein.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides demonstrate potent and selective activity for ABCA1, promoting cholesterol efflux, reducing atherosclerosis severity, and stabilizing plaques, offering a therapeutic option for cardiovascular diseases with improved pharmacokinetic and pharmacodynamic properties.
Implementation Method 1
polypeptides having high-affinity binding to ABCA1, stimulating cholesterol efflux and stabilizing the ABCA1 transporter
Data Source
AI summary
The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABAC1 that parallels that of full-length apolipoproteins. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.